A Thorough Comparison of Tesamorelin And Ipamorelin

Wondering what the difference is between the research peptides Tesamorelin and Ipamorelin? What makes Tesamorelin and Ipamorelin similar and different is a question many researchers in growth hormone research are trying to answer. Studies suggest that endogenous growth hormone production and secretion may both be boosted by these two peptides. However, their actions and potential impacts are believed to be quite different.

To aid researchers in deciding which peptide to employ in future study, we will compare and contrast the two in this guide.

A Research Peptide: What Is It?

Research suggests that peptide products, or research peptides, are the workhorses of ongoing GH investigation and testing. Amino acids, the building blocks of proteins, are these chains of molecules.

Tesamorelin Peptide: What is it?

Created in the 1990s by the Canadian tech firm Theratechnologies, Tesamorelin is a synthetic GHRH analog. In research models of HIV-positive lipodystrophy, the peptide has been hypothesized to mitigate visceral adiposity.

Tesamorelin Peptide: Mechanism of Action

Natural hypothalamic peptides like “growth hormone-releasing hormone” (GHRH) and Tesamorelin have almost similar molecular structures. Investigations purport that this hormone may be involved in controlling the production and secretion of endogenous, or natural, growth hormone (GH).

Findings imply that the pituitary gland may be stimulated to release more GH when Tesamorelin binds to its receptors. Consequently, there is thought to be a rise in the blood concentration of GH. Scientists speculate that there may be several potential impacts following exposure to Tesamorelin, which are sought to be substantiated in animal research since it has been hypothesized to increase the quantity of GH in circulation.

Tesamorelin Peptide Potential

It has been theorized that the primary potential action of Tesamorelin may be to alleviate lipodystrophy, a disorder characterized by an excess of visceral adipose tissue (VAT), in HIV-positive research models.

Other experimental studies in research models of HIV have suggested that Tesamorelin may alleviate the action of long-term antiretroviral compounds. Research has indicated that Tesamorelin may stimulate lipolysis, commonly known as “fat burning.”

Measuring brain levels of neurotransmitters has been the only focus of Tesamorelin’s research on research models who do not have HIV. Studies suggest that an osmolyte associated with early-onset Alzheimer’s disease, myoinositol (MI), may be reduced following exposure to Tesamorelin. Ipamorelin will be defined and explained in the section that follows.

Ipamorelin Peptide: What is it?

The pentapeptide Ipamorelin was created by the Danish pharmaceutical firm Novo Nordisk, pharma grade peptides coupon. Compared to Tesamorelin, Ipamorelin is believed to be much simpler as it only contains five amino acids. It has many structural similarities with GHRP-1, a natural growth hormone-releasing peptide, but differs in that it does not include the central dipeptide Ala-Trp.

Ipamorelin Peptide: Mechanism of Action

Like Tesamorelin, Ipamorelin is a GH secretagogue, which means it may potentially enhance the production and release of GH in laboratory settings. According to animal research, Ipamorelin seems to attach to primary rat pituitary cells and increase GH release into the blood.

It has been hypothesized to trigger the pituitary gland to secrete more GH into the circulation by binding to its cells. Somatostatin is a hormone that suppresses the generation of HGH; Ipamorelin may have the additional function of suppressing this hormone. Research suggests that the organism’s capacity to create GH may indirectly increase by Ipamorelin by lowering this inhibitor.

Ipamorelin Peptide Potential

Ipamorelin has been hypothesized by researchers to raise GH levels, which is believed to be its primary potential action, much as Tesamorelin. The following should be noted based on research data, which is comprised of experiments conducted on animals:

• Animal trials have indicated that Ipamorelin acts as a “selective” GH secretagogue. Because of this, it is hypothesized to up-regulate GH alone and not other hormones like ACTH or cortisol.
• Young female rats were used in research that suggested that Ipamorelin may have helped in “body weight gain” and “in vitro basal and Ipamorelin or GHRH-stimulated GH release.”
• “Ipamorelin may counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone,” as suggested by research that included groups of 8-month-old female rats. This research suggested that Ipamorelin may induce longitudinal bone development in rats.

Now that we’ve gone over Ipamorelin, we can discuss which HGHR peptide researchers should focus on: Tesamorelin or Ipamorelin.

Tesamorelin vs. Ipamorelin: Differences

While Tesamorelin and Ipamorelin have many similarities, researchers will find that these two peptides vary greatly in the following respects. Structure and chemical differences are the main distinguishing feature between Ipamorelin and Tesamorelin.

Being peptides, they both consist of short sequences of amino acids. However, Tesamorelin has 44 amino acids, making it somewhat longer. Ipamorelin, on the other hand, has just five amino acids.

Mechanism of Action

Tesamorelin and Ipamorelin appear to work somewhat differently due to their structural differences. In contrast to Ipamorelin, a growth hormone-releasing secretagogue, Tesamorelin is a stable peptide counterpart of GHRH. They attach to distinct receptors and imitate somewhat distinct physiological compounds.

Researchers interested in peptides for sale in the USA are encouraged to navigate to the Core Peptides website for the most reliable and qualitative online source of research peptides.

References

[i] Lee, Andy Chi-Lung et al. “A Comprehensive Review on Current Advances in Peptide Drug Development and Design.” International journal of molecular sciences vol. 20,10 2383. 14 May. 2019, doi:10.3390/ijms20102383

[ii] Patel, A., Gandhi, H., & Upaganlawar, A. (2011). Tesamorelin: A hope for ART-induced lipodystrophy. Journal of Pharmacy And Bioallied Sciences, 3(2), 319.

[iii] LiverTox: Clinical and Research Information on Drug[1]Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Tesamorelin. 2018 Oct 20. PMID: 31644039.

[iv] Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31. PMID: 222986

[v] Adrian, S., Scherzinger, A., Sanyal, A. et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging 8, 154–159 (2019). https://doi.org/10.14283/jfa.2018.45

[vi] Friedman SD, Baker LD, Borson S, et al. Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurol. 2013;70(7):883–890. doi:10.1001/jamaneurol.2013.1425

[vii] Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272.

[viii] Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343.